flavivirus
small
envelop
singlestrand
positivesens
rna
virus
caus
seriou
diseas
human
anim
flavivirus
arthropodborn
virus
transmit
vertebr
host
either
mosquito
tick
sever
member
flaviviru
genu
zika
viru
zikv
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
highli
pathogen
human
recent
outbreak
flavivirus
rais
global
concern
sinc
sever
report
link
recent
zikv
outbreak
america
increas
microcephali
case
fetus
newborn
increas
syndrom
case
addit
recent
yfv
outbreak
africa
caus
approxim
death
henc
flavivirus
pose
global
threat
popul
especi
area
naiv
infect
climat
chang
increas
mobil
peopl
flavivirus
emerg
outsid
endem
area
order
limit
flaviviru
outbreak
antivir
drug
urgent
need
howev
date
approv
antivir
therapi
flavivirus
sever
preclin
investig
drug
assess
antiflaviviru
activ
howev
flavivirus
often
escap
antivir
target
specif
viral
protein
high
mutat
rate
given
lack
specif
treatment
option
flavivirus
host
direct
therapi
could
repres
strategi
discoveri
panflaviviru
antivir
agent
previous
identifi
optim
antiadenovir
compound
result
figur
novel
antivir
compound
broad
antivir
activ
dna
virus
human
adenoviru
hadv
herp
simplex
viru
type
type
recent
rna
viru
rift
valley
fever
viru
rvfv
explor
antivir
activ
flavivirus
urgent
need
effect
therapeut
intervent
use
zoanthu
speci
green
fluoresc
protein
zsgreen
express
infecti
zikv
primari
tool
studi
antiflaviviru
activ
expand
investig
effect
wildtyp
wt
zikv
sever
pathogen
flavivirus
antivir
activ
compar
activ
antivir
drug
favipiravir
ribavirin
recent
report
display
antivir
activ
flavivirus
studi
demonstr
potent
antivir
activ
flavivirus
thu
ad
new
group
virus
broad
spectrum
antivir
activ
studi
experi
perform
biocontain
level
laboratori
except
experi
focusform
assay
antivir
assay
flavivirus
perform
biocontain
level
laboratori
plasmid
contain
fulllength
infecti
clone
icdna
brazilian
zikv
isol
contain
zsgreen
report
kindli
provid
dr
merit
tartu
univers
tartu
estonia
strategi
previous
describ
zikv
icdna
rescu
use
briefli
linear
use
agei
restrict
enzym
prior
vitro
transcript
result
dna
fragment
purifi
use
nucleospin
gel
pcr
cleanup
kit
machereynagel
germani
elut
water
mmessag
mmachin
transcript
kit
thermo
scientif
usa
use
synthes
vitro
transcrib
rna
cdna
reaction
volum
cap
rna
transcript
transfect
vero
cell
use
transfect
kit
miru
bio
madison
wi
usa
transfect
cell
monitor
daili
signific
cytopathogen
effect
zsgreen
signal
observ
stock
rescu
virus
rzikvzsgreen
passag
number
stock
harvest
centrifug
rpm
min
remov
cellular
debri
aliquot
fetal
bovin
serum
fb
aliquot
store
use
viru
concentr
stock
determin
plaqu
assay
previous
describ
briefli
tenfold
serial
dilut
viru
sampl
ad
plate
contain
confluent
monolay
vero
cell
h
incub
shake
everi
min
viru
suspens
discard
overlay
ad
contain
ml
dulbecco
modifi
eagl
medium
dmem
fb
minimum
essenti
amino
acid
sodium
pyruv
lglutamin
penicillinstreptomycin
carboxymethylcellulos
cmc
sigma
aldrich
st
loui
mo
usa
day
incub
cell
fix
paraformaldehyd
stain
crystal
violet
solut
crystal
violet
powder
wv
methanol
distil
plaqu
count
viral
titer
calcul
plaqueform
unit
pfu
ml
propag
stock
confluent
vero
cell
grown
flask
sarstedt
germani
infect
multipl
infect
moi
supernat
stock
collect
cytopath
effect
cpe
zsgreen
signal
observ
stock
titrat
use
doserespons
analysi
time
addit
assay
isol
zikv
collect
sentinel
rhesu
monkey
zika
forest
uganda
april
kindli
provid
dr
g
dobler
bundeswehr
institut
microbiolog
munich
germani
zikv
strain
gi
isol
brazil
rescu
icdna
tbev
strain
kindli
provid
dr
g
dobler
bundeswehr
institut
microbiolog
munich
germani
yfv
strain
asibi
kindli
provid
dr
niedrig
robert
koch
institut
berlin
germani
jev
strain
nakayama
wnv
isol
israel
passag
number
pngnew
guinea
c
strain
kind
gift
dr
vene
public
health
agenc
sweden
stockholm
sweden
viru
strain
amplifi
titrat
vero
cell
vero
cell
african
green
monkey
kidney
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
acid
hepe
penicillinstreptomycin
viru
infect
cell
mainten
medium
use
contain
compon
except
lower
fb
concentr
ribavirin
purchas
sigma
aldrich
st
loui
mo
usa
favipiravir
purchas
selleckchem
munich
germani
compound
synthes
previous
describ
dissolv
dmso
chemic
structur
compound
analyz
studi
illustr
figur
six
compound
analyz
use
fluoresc
intens
assay
quantifi
zsgreen
express
previous
describ
day
infect
vero
cell
per
well
seed
black
plate
transpar
bottom
corn
corn
ny
usa
next
day
compound
twofold
seriallydilut
nine
step
dimethyl
sulfoxid
dmso
final
concentr
dmso
compound
mixtur
mix
pfu
rzikvzsgreen
viru
total
volum
compoundviru
mixtur
ad
cell
plate
incub
h
incub
incub
medium
remov
cell
fix
paraformaldehyd
h
room
temperatur
wash
phosphatebuff
salin
pb
fix
cell
counterstain
nm
dapi
pb
tropho
plate
runner
tropho
roch
group
basel
switzerland
identifi
individu
zsgreenexpress
cell
dapistain
cell
quantifi
fluoresc
intens
well
infect
rate
calcul
divid
number
infect
cell
zsgreenexpress
cell
total
number
cell
dapistain
cell
valu
calcul
nonlinear
regress
analysi
variabl
slope
use
graphpad
prism
softwar
furthermor
valu
calcul
quick
calc
provid
graphpad
websit
cellular
toxic
compound
assess
use
resazurin
cell
viabil
assay
assess
metabol
activ
live
cell
analyz
cell
viabil
post
compound
treatment
final
concentr
resazurin
ad
per
well
incub
h
incub
fluoresc
intens
measur
nm
emiss
spectra
nm
vero
cell
cell
per
well
seed
plate
day
prior
infect
two
wt
zikv
lineag
pfu
togeth
dmem
cmc
ad
cell
incub
day
next
cell
fix
neutralbuff
formalin
stain
crystal
violet
solut
crystal
violet
powder
wv
methanol
distil
measur
plaqu
use
opensourc
softwar
solut
vero
cell
seed
plate
cell
per
well
wt
zikv
pfu
solut
togeth
dmem
ad
cell
incub
day
supernat
collect
infect
cell
without
compound
next
collect
supernat
transfer
new
vero
cell
layer
indic
cell
h
replac
dmem
cmc
cpe
observ
crystal
violet
stain
fresh
dmem
qrtpcr
respect
plate
analyz
observ
virusinduc
cpe
day
postinfect
plaqu
format
determin
crystal
violet
stain
day
supernat
collect
use
viral
rna
isol
quantif
viru
rna
supernat
quantifi
viru
rna
supernat
viral
rna
isol
supernat
use
viral
rna
isol
kit
macherey
nagel
dueren
germani
first
strand
synthesi
kit
zikv
specif
primer
use
synthes
cdna
thermo
fisher
waltham
usa
perform
realtim
qpcr
synthes
cdna
use
templat
mixtur
sybr
master
mix
kapa
biosystem
switzerland
zikv
specif
primer
forward
gtacatggactacctatccacc
revers
ctgactagcaggcctgacaac
qpcr
reaction
carri
realtim
pcr
system
thermo
fisher
waltham
usa
obtain
cycl
threshold
ct
valu
convert
actual
copi
number
zikv
gene
use
standard
curv
gener
zikv
gene
standard
curv
bp
zikv
pcr
amplicon
clone
vector
thermo
fisher
waltham
usa
logarithm
base
concentr
copi
number
prepar
qpcr
reaction
perform
obtain
ct
valu
convert
standard
curv
use
graphpad
prism
softwar
graphpad
softwar
san
diego
ca
usa
detect
limit
copi
zikv
gene
fluoresc
intens
assay
quantifi
zsgreen
express
zikvzsgreen
vector
use
timeofaddit
assay
briefli
vero
cell
per
well
seed
black
plate
transpar
bottom
day
prior
experi
perform
assay
pretreat
condit
h
media
well
replac
dmem
contain
fb
h
well
infect
moi
rzikvzsgreen
h
replac
fresh
dmem
h
well
ad
togeth
viru
hpi
viru
remov
well
ad
everi
second
hour
h
puls
h
h
h
h
h
sampl
h
cell
treat
togeth
viru
h
medium
replac
dmem
extra
h
h
infect
cell
fix
paraformaldehyd
wash
pb
fix
cell
counterstain
nm
dapi
pb
tropho
plate
runner
hd
tropho
roch
group
basel
switzerland
identifi
individu
zsgreenexpress
cell
quantifi
fluoresc
intens
well
monolay
vero
cell
infect
zikv
tbev
wnv
jev
yfv
multipl
infect
moi
dmem
contain
either
dmso
ribavirin
h
h
infect
inoculum
replac
dmem
penicillinstreptomycin
fb
supplement
either
dmso
ribavirin
supernat
harvest
hpi
tbev
zikv
hpi
wnv
jev
yfv
titer
determin
use
focusform
assay
previous
describ
brief
virus
dilut
use
infect
vero
cell
viral
foci
detect
use
primari
monoclon
mous
antibodi
dilut
direct
tbev
flaviviru
e
wnv
jev
atcc
yfv
atcc
primari
antibodi
incub
secondari
horseradish
peroxidaseconjug
antimous
antibodi
thermo
fisher
scientif
ad
follow
trueblu
peroxidas
substrat
kpl
gaithersburg
md
usa
mean
standard
deviat
sd
calcul
graphpad
prism
softwar
statist
analys
perform
use
oneway
analysi
varianc
anova
dunnett
posthoc
analysi
use
multipl
comparison
test
graphpad
prism
softwar
p
consid
statist
signific
explor
antizikv
activ
assess
inhibit
zsgreen
express
infect
recombin
zikv
rzikvzsgreen
recombin
infecti
viru
zsgreen
gene
fuse
sequenc
encod
foot
mouth
diseas
viru
fmdv
autoproteas
clone
inbetween
two
copi
sequenc
encod
zikv
capsid
protein
figur
infect
rzikvzsgreen
similar
compar
wildtyp
zikv
previous
report
inhibitori
effect
compound
figur
rzikvzsgreen
express
assess
dosedepend
manner
figur
tabl
display
highest
potenc
among
compound
valu
valu
ribavirin
antivir
activ
favipiravir
detect
test
concentr
rang
highest
concentr
precursor
display
lower
potenc
compar
two
structurallyrel
analog
show
antivir
activ
reduc
potenc
respect
result
line
previou
observ
herp
simplex
viru
hsv
human
adenoviru
hadv
rift
valley
fever
viru
rvfv
host
cell
toxic
structur
analog
previous
assess
use
cell
type
vero
previous
report
solubl
issu
cell
media
observ
henc
set
maximum
concentr
toxic
assess
compound
vero
cell
toxic
analyz
h
posttreat
use
resazurinbas
toxic
test
colorimetr
assay
measur
metabol
activ
live
cell
compound
display
cell
viabil
well
highest
concentr
thu
valu
could
measur
select
index
si
could
present
tabl
confirm
antivir
activ
exclud
observ
inhibit
specif
rzikvzsgreen
analyz
whether
inhibit
wt
zikv
plaqu
format
format
plaqu
correspond
full
infect
cycl
entri
egress
newlyform
viral
particl
base
doserespons
activ
rzikvzsgreen
vector
figur
tabl
conduct
plaqu
format
assay
dosedepend
manner
use
ribavirin
observ
plaqu
form
inhibit
clinic
relev
wt
zikv
asian
lineag
brazil
strain
day
zikv
infect
vero
cell
fix
plaqu
visual
crystal
violet
stain
quantifi
show
signific
reduct
plaqu
format
appli
concentr
ribavirin
show
inhibit
plaqu
format
figur
investig
inhibit
wt
zikv
lineag
treat
african
lineag
uganda
strain
show
signific
reduct
plaqu
format
reduct
african
lineag
reduct
asian
lineag
figur
reduct
wt
zikv
plaqu
format
investig
analyz
product
infecti
progeni
particl
supernat
infect
cell
supernat
cell
infect
two
wt
zikv
lineag
asian
african
treat
see
collect
use
infect
vero
cell
layer
infect
effici
determin
observ
cpe
plaqu
format
qrtpcr
see
schemat
diagram
figur
day
postprogeni
viru
transfer
cell
infect
progeni
viru
treat
cell
display
minor
cpe
day
cell
fix
stain
crystal
violet
visual
infect
plaqu
format
cell
infect
progeni
viru
cell
display
visibl
plaqu
figur
quantifi
antivir
effect
harvest
supernat
day
postprogeni
viru
transfer
viral
rna
supernat
measur
use
qrtpcr
reduct
viru
rna
copi
number
supernat
treat
cell
african
zikv
brazilian
zikv
figur
conclud
effici
inhibit
product
infecti
progeni
viru
obtain
insight
modeofact
timeofaddit
experi
perform
vero
cell
infect
rzikvzsgreen
ad
differ
time
point
pretreat
h
everi
second
hour
h
puls
h
h
h
h
h
h
base
growth
kinet
rzikvzsgreen
sensit
zsgreen
detect
fluoresc
intens
assay
analysi
viru
infect
perform
h
postinfect
treatment
scheme
rel
high
concentr
select
figur
ad
h
postinfect
hpi
inhibitori
effect
pronounc
bind
entri
step
h
less
affect
addit
later
timepoint
postinfect
also
show
less
inhibit
although
preincub
cell
prior
infect
h
inhibitori
effect
much
lower
compar
addit
earli
phase
h
infect
figur
member
flaviviru
genu
caus
sever
morbid
mortal
mankind
worldwid
sinc
display
potent
activ
rzikvzsgreen
vector
two
wt
zikv
lineag
assess
flavivirus
medic
import
inhibit
vero
cell
infect
six
member
flaviviru
genu
zikv
tbev
wnv
jev
yfv
presenc
ribavirin
supernat
harvest
h
h
postinfect
titer
determin
focusform
assay
ribavirin
show
approxim
tenfold
signific
reduct
four
flavivirus
zikv
tbev
yfv
viral
titer
reduct
zikv
tbev
yfv
signific
activ
detect
jev
wnv
figur
strikingli
treatment
show
signific
reduct
infect
six
flavivirus
analyz
viral
titer
reduct
zikv
tbev
wnv
jev
yfv
result
confirm
potent
broadspectrum
activ
flaviviru
infect
major
public
health
problem
annual
million
peopl
infect
flavivirus
caus
signific
health
econom
social
burden
worldwid
viru
endem
mani
countri
caus
devast
outbreak
widespread
zikv
outbreak
america
associ
sever
neurolog
disord
ie
microcephali
syndrom
africa
yfv
reemerg
caus
death
antivir
drug
avail
treat
flaviviru
infect
henc
urgent
need
proper
antivir
therapi
order
control
forthcom
outbreak
previous
discov
novel
antiadenovir
compound
subsequ
medicin
chemistri
program
result
potent
broadspectrum
antivir
compound
present
potent
antivir
activ
dnavirus
hadv
respect
acyclovirresist
clinic
hsv
isol
recent
report
activ
vitro
negativesens
singl
strand
rnaviru
rvfv
describ
antivir
activ
positivesens
singlestrand
rna
virus
flaviviru
genu
togeth
activ
three
structur
analog
two
commerci
antivir
drug
previouslyreport
antiflaviviru
activ
recombin
zikv
zsgreeninsert
rzikvzsgreen
brazilian
strain
isol
valuabl
screen
tool
infect
easili
quantifi
infect
recombin
viru
similar
wt
zikv
use
recombin
viru
primari
assess
antizikv
activ
doserespons
studi
reveal
submicromolar
valu
valu
wherea
two
commerci
antivir
drug
ribavirin
favipiravir
includ
posit
control
moder
antivir
activ
respect
ribavirin
wellknown
nucleotid
analog
antiflaviviru
activ
previous
report
ribavirin
show
moder
antizikv
activ
assay
valu
valu
consist
previou
report
display
variabl
efficaci
rang
ribavirin
zikv
favipiravir
fail
display
antizikv
activ
assay
lei
cai
et
al
show
valu
favipiravir
highest
compound
concentr
assay
thu
antivir
activ
might
observ
increas
concentr
favipiravir
three
structur
analog
figur
includ
studi
assess
whether
activ
profil
zikv
correspond
previou
find
hadv
hsv
rvfv
studi
potent
compound
valu
rang
follow
less
potent
compound
less
efficaci
accur
could
determin
virus
interestingli
follow
sigmoid
doserespons
curv
previous
report
result
narrow
concentr
rang
valu
howev
reason
phenomenon
unknown
may
contribut
understand
modeofact
compound
class
confirm
antivir
activ
shift
therapeut
relev
wt
zikv
conduct
plaqu
format
assay
dosedepend
manner
use
ribavirin
brazilian
zikv
strain
show
signific
reduct
plaqu
format
appli
concentr
ribavirin
show
signific
inhibit
figur
examin
plaqu
inhibit
activ
anoth
zikv
lineag
use
african
zikv
african
uganda
strain
previous
plaqu
format
strain
describ
quantif
plaqu
format
ideal
assess
antivir
compound
sinc
endpoint
readout
plaqu
format
includ
full
infect
cycl
show
signific
inhibit
plaqu
format
zikv
lineag
african
reduct
asian
lineag
assess
inhibit
plaqu
format
quantifi
product
infecti
progeni
viru
strongli
inhibit
product
progeni
zikv
viru
particl
releas
cellular
surround
drug
develop
physiolog
perspect
pronounc
inhibit
progeni
viru
product
favor
ultim
aim
antivir
drug
diminish
viral
spread
flavivirus
share
sever
common
cellular
factor
infecti
cycl
might
specif
target
previou
find
broadspectrum
antivir
activ
inhibit
dna
rna
virus
indic
could
act
host
cell
target
elucid
zikv
infecti
cycl
target
could
present
perform
timeofaddit
analysi
reveal
effect
earli
timepoint
zikv
infecti
cycl
inhibit
bind
entri
extent
pronounc
inhibit
found
present
h
infect
could
indic
effect
protein
translat
protein
matur
earli
replic
assembl
replic
vesicl
zikv
infecti
cycl
previous
perform
similar
timeofaddit
analysi
rvfv
pronounc
inhibit
also
earli
timepoint
precis
h
infect
indic
rvfv
bind
endocytosi
primari
transcript
protein
translat
might
inhibit
discrep
time
activ
rvfv
zikv
might
explain
differ
kinet
two
virus
rvfv
known
rapid
infecti
cycl
compar
zikv
henc
possibl
util
target
act
upon
earlier
also
indic
interf
gener
endocytosi
infect
might
inhibit
membran
rearrang
need
er
flaviviru
replic
neg
strand
rna
viru
rvfv
share
featur
lack
avail
antivir
drug
treat
flavivirus
made
us
assess
antivir
activ
addit
medicallyimport
member
flaviviru
genu
antivir
effect
ribavirin
assess
focu
form
assay
six
differ
wildtyp
flavivirus
classifi
tbev
wnv
jev
yfv
classifi
zikv
refer
strikingli
display
potent
antivir
activ
reduc
viral
titer
three
five
order
magnitud
test
flavivirus
conclud
potent
antivir
compound
broadspectrum
activ
span
across
dna
rna
virus
describ
antivir
activ
flavivirus
greatunmet
medic
need
antivir
therapi
elucid
precis
cellular
target
modeofact
efficaci
vivo
ongo
contribut
develop
new
effect
antivir
drug
